Phathom Pharmaceuticals (PHAT) to Release Quarterly Earnings on Thursday

Phathom Pharmaceuticals (NASDAQ:PHAT) is expected to be posting its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Phathom Pharmaceuticals to post earnings of ($0.09) per share and revenue of $57.4440 million for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:00 AM ET.

Phathom Pharmaceuticals Stock Down 0.4%

NASDAQ PHAT opened at $11.37 on Tuesday. Phathom Pharmaceuticals has a fifty-two week low of $2.21 and a fifty-two week high of $18.31. The business has a 50 day moving average price of $14.59 and a two-hundred day moving average price of $13.45. The stock has a market cap of $812.05 million, a PE ratio of -2.98 and a beta of 0.51.

Analyst Ratings Changes

PHAT has been the subject of several analyst reports. Barclays assumed coverage on shares of Phathom Pharmaceuticals in a research note on Monday, December 8th. They issued an “equal weight” rating and a $16.00 target price for the company. Craig Hallum reiterated a “buy” rating and issued a $22.00 price objective on shares of Phathom Pharmaceuticals in a report on Friday, October 31st. Weiss Ratings reissued a “sell (d-)” rating on shares of Phathom Pharmaceuticals in a research report on Thursday, January 22nd. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Phathom Pharmaceuticals in a research report on Wednesday, January 14th. Finally, Raymond James Financial began coverage on Phathom Pharmaceuticals in a research note on Thursday, December 11th. They issued a “strong-buy” rating and a $28.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $20.71.

Hedge Funds Weigh In On Phathom Pharmaceuticals

Large investors have recently modified their holdings of the stock. AQR Capital Management LLC grew its stake in Phathom Pharmaceuticals by 508.2% in the first quarter. AQR Capital Management LLC now owns 107,399 shares of the company’s stock worth $673,000 after purchasing an additional 89,741 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in Phathom Pharmaceuticals by 0.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 138,516 shares of the company’s stock worth $1,328,000 after buying an additional 1,123 shares during the last quarter. Rhumbline Advisers lifted its holdings in Phathom Pharmaceuticals by 13.8% during the 2nd quarter. Rhumbline Advisers now owns 64,557 shares of the company’s stock worth $619,000 after buying an additional 7,818 shares during the last quarter. Invesco Ltd. grew its position in shares of Phathom Pharmaceuticals by 13.4% in the 2nd quarter. Invesco Ltd. now owns 4,140,072 shares of the company’s stock worth $39,703,000 after acquiring an additional 489,260 shares in the last quarter. Finally, Nebula Research & Development LLC grew its position in shares of Phathom Pharmaceuticals by 31.6% in the 2nd quarter. Nebula Research & Development LLC now owns 37,937 shares of the company’s stock worth $364,000 after acquiring an additional 9,116 shares in the last quarter. Institutional investors own 99.01% of the company’s stock.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals is a clinical‐stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The company’s core mission centers on addressing serious GI disorders by leveraging innovative mechanisms of action to improve patient outcomes. Phathom’s research and development efforts concentrate on conditions such as Helicobacter pylori infection, erosive esophagitis, gastroparesis and other functional GI disorders where significant unmet medical needs persist.

The company’s lead asset is vonoprazan, a potassium‐competitive acid blocker (P-CAB) licensed for use in the United States.